€ 6au 1615 1103326-0283



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Yicants: Löfroth. et al.

Serial No.: 08/945,655

Examiner

E. Webman

Filed

: October 24, 1997

Group Art Unit: 1615

For

: PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE OF

THE HMG-COA REDUCTASE INHIBITOR FLUVASTATIN

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231, on April 20, 1999.

Richard J. Sterner

Agent Name

Signature

35,372

PTO Reg. No.

April 20, 1999

Date of Signature

RECEIVED

The Assistant Commissioner for Patents Washington, D.C. 20231

APR 2 6 1999

INFORMATION DISCLOSURE STATEMENT

MATRIX GUSTOMER SERVICE CENTER

Sir:

In compliance with 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the two (2) references listed on the attached Form PTO-1449 be made of record in this application. Copies of the references are enclosed. These references were cited in the International Search Report, a copy of which was previously submitted to the PTO as Designated Office.

This communication is submitted prior to the issuance of a timely first office action, and no fee should be due. However, should it be determined that a fee is required for any reason, the Assistant Commissioner is hereby authorized to charge it to Deposit Account No. 23-1703.

Dated: April 20, 1999

Respectfully submitted,

Richard J. Sterner Reg. No. 35,372

White & Case LLP 1155 Avenue of the Americas New York, NY 10036 (212) 819-8783

Enclosures